Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Thailand to Buy Generic Plavix in India, Snubs Sanofi (Thailand)

This article was originally published in PharmAsia News

Executive Summary

Thailand is ordering 2 million doses of generic Plavix from India after failing to win large enough discounts for the blood-thinner made by Bristol-Myers Squibb Co. and Sanofi-Aventis SA. As many as four Indian drugmakers are vying for the contract, according to Vichai Chokevivat, chairman of the Government Pharmaceutical Organization. The supplies will help meet Thailand's demand for between 4 million and 5 million Plavix tablets a year and cut the cost of treating the country's poorest heart-disease patients. The state-run drugmaker, which had initially sought 500,000 doses of generic Plavix, or clopidogrel, expects to pay between 5 baht and 5.50 baht for the pills. Sanofi offered to sell Plavix at 27 baht per tablet, with an added incentive of supplying 3.4 million tablets for the same cost as 1 million. "We proposed a program that would allow the Ministry of Public Health to supply, at no additional cost, our high-quality heart treatment," Sanofi spokesman Jean-Marc Podvin said. "However, the ministry has focused only on price and has insisted repeatedly on sourcing generics of Plavix of unknown quality." Thailand is using a World Trade Organization provision that allows governments to permit generic-drug production without the patent owners' consent in some cases. Thailand is already buying copies of the AIDS drug efavirenz, marketed as Stocrin by Merck & Co. and as Sustiva by Bristol-Myers, from an Indian unit of Mylan Laboratories Inc. Thailand says copying the drugs will allow the government to provide free medicine to a larger share of the country's poorest citizens, including its 220,000 HIV sufferers. The Pharmaceutical Research and Manufacturers of America says issuing so-called compulsory licenses removes the incentive for companies to invest in research, and that its members would retaliate by not introducing new drugs in Thailand. (Click here for more - May Require Free Registration

You may also be interested in...

Gilead’s Comparative Analysis To Bolster Remdesivir Draws Criticism

Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.

US FDA Announces Plans To Resume Domestic Inspections

Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.

Finance Watch: Poseida, Nkarta And Inventiva Are July’s First Biopharma IPOs

Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts